title: [Effect of mistletoe lectin therapy on serum level of defined serum proteins (acute phase proteins) in tumor patients].
abstract: The influence of galactoside-specific mistletoe lectin (ML-1) administration on defined acute phase reactants in the serum of cancer patients (mammary carcinoma, n = 4; larynx carcinoma, n = 11; TNM-stages II to IV; after appropriate surgery, chemotherapy, radiation) was studied. Regular subcutaneous injections of the optimal doses of ML-1 (1 mg/kg body weight, twice a week) yielded statistically significant increases of certain acute phase reactants (C-reactive protein, haptoglobin, coeruloplasmin, C3-complement, albumin, immunoglobulin IgM) after four weeks of treatment. However, serum concentrations of transferrin, C4-complement and the immunoglobulins IgG and IgA were found within the biological range (means +/- 2 s). The increase of acute phase reactants after administration of ML-1 correlates positively with the activity of lymphatic cells (e.g. expression of IL-2 and HLA-DR receptors) in FACS (fluorescence-activated cell sorter) staining experiments and indicates the immunoreactive potency of this substance which may be speculated to be cytokine-induced.
authors.affiliation: Institut für Medizinische Mikrobiologie und Hygiene der Universität zu Köln.
authors.forename: J
authors.initials: J
authors.lastname: Beuth
authors.forename: H J
authors.initials: HJ
authors.lastname: Gabius
authors.forename: M K
authors.initials: MK
authors.lastname: Steuer
authors.forename: J
authors.initials: J
authors.lastname: Geisel
authors.forename: M
authors.initials: M
authors.lastname: Steuer
authors.forename: H L
authors.initials: HL
authors.lastname: Ko
authors.forename: G
authors.initials: G
authors.lastname: Pulverer
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism*; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D016207:Cytokines / Q000097:blood; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D007822:Laryngeal Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological / Q000008:administration & dosage*
chemical_list: D000209:Acute-Phase Proteins; D003176:Complement C3; D003181:Complement C4; D016207:Cytokines; D007136:Immunoglobulins; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum